Keyphrases
BRCA2
100%
Cyclin C
100%
CRISPR Interference (CRISPRi)
100%
PARP Inhibitor (PARPi)
66%
Inhibitor Resistance
50%
Genetic Modification
16%
Cancer Patients
16%
Improved Survival
16%
Resistance Mechanisms
16%
In Cancer
16%
Tumor Burden
16%
Knockout Cells
16%
Cell Survival
16%
Acquired Resistance
16%
Novel Therapeutics
16%
BRCA mutation
16%
Loss Function
16%
Whole Genome
16%
Homologous Recombination Repair
16%
Genetic Determinants
16%
BRCA2 mutation
16%
MRNA-seq
16%
Transforming Growth Factor-β Signaling
16%
Extracellular Matrix Receptors
16%
Receptor-ligand Interaction
16%
Interaction Pathway
16%
DNA Damage Signaling
16%
Complex Components
16%
RNA Polymerase II Transcription
16%
Mediator Complex
16%
Gene Essentiality
16%
Replication Fork Stability
16%
Biochemistry, Genetics and Molecular Biology
BRCA2
100%
Cyclin C
100%
CRISPR
100%
Poly ADP Ribose Polymerase
57%
Genetics
14%
Gene Mutation
14%
Tumor Volume
14%
Messenger RNA
14%
Homologous Recombination
14%
RNA Polymerase II
14%
DNA Damage
14%
Cell Survival
14%
BRCA1
14%
Recombination Repair
14%
Transforming Growth Factor Beta
14%
Mediator Complex
14%
Immunology and Microbiology
Cyclin C
100%
Clustered Regularly Interspaced Short Palindromic Repeat
100%
Gene Mutation
16%
RNA Polymerase
16%
DNA Damage
16%
Homologous Recombination
16%
Tumor Volume
16%
Extracellular Matrix
16%
Recombination Repair
16%
Cell Survival
16%
Transforming Growth Factor Beta
16%
Mediator Complex
16%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclin C
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
66%
Neoplasm
16%
Malignant Neoplasm
16%
Messenger RNA
16%
RNA Polymerase II
16%
Receptor
16%
Transforming Growth Factor Beta
16%
Mediator Complex
16%